Labs and Path Groups Should Prepare for Arrival of ‘Perfect Storm’
In the near future, clinical labs and pathology groups will need to address three major developments. One involves the FDA proposed LDT rule. A second is the adoption by payers of guidelines that require genetic test claims to have Z-Codes. The third centers around coming reforms and updates to the 1992 CLIA rules. This is […]
Labs and Path Groups Should Prepare for Arrival of ‘Perfect Storm’ Read More »